BACKGROUND: Previous studies suggested a decreased risk of cancer among patients with Alzheimer's disease (AD). There is still a lack of data on the specific types of cancer, the risk factors, and the impact of cholinesterase inhibitors on developing cancer in AD. METHODS: We performed a nationwide population-based study of 6,960 patients with AD between 1997 and 2006 using Taiwan's National Health Insurance database. Patterns of cancer incidence in AD patients were compared with those of the general population using standardized incidence ratios (SIRs). RESULTS: Patients with AD had a reduced risk of developing overall cancer [SIR = 0.88, 95% confidence interval (CI) = 0.80-0.97]. Specifically, patients with AD were protected from lung cancers (SIR = 0.75, 95% CI = 0.57-0.98), especially men (SIR = 0.61, 95% CI = 0.40-0.88). In subgroup analyses, women, patients aged 60-79 years, and those diagnosed as having AD for more than 1 year were more likely to be protected from cancers. CONCLUSIONS: Our study demonstrates a decreased incidence of overall cancers in patients with AD, a finding lower than but consistent with Western countries. Patients with AD had a significantly decreased risk of lung cancer. Further investigation of genetic evidence linking AD to cancer is warranted.
BACKGROUND: Previous studies suggested a decreased risk of cancer among patients with Alzheimer's disease (AD). There is still a lack of data on the specific types of cancer, the risk factors, and the impact of cholinesterase inhibitors on developing cancer in AD. METHODS: We performed a nationwide population-based study of 6,960 patients with AD between 1997 and 2006 using Taiwan's National Health Insurance database. Patterns of cancer incidence in ADpatients were compared with those of the general population using standardized incidence ratios (SIRs). RESULTS:Patients with AD had a reduced risk of developing overall cancer [SIR = 0.88, 95% confidence interval (CI) = 0.80-0.97]. Specifically, patients with AD were protected from lung cancers (SIR = 0.75, 95% CI = 0.57-0.98), especially men (SIR = 0.61, 95% CI = 0.40-0.88). In subgroup analyses, women, patients aged 60-79 years, and those diagnosed as having AD for more than 1 year were more likely to be protected from cancers. CONCLUSIONS: Our study demonstrates a decreased incidence of overall cancers in patients with AD, a finding lower than but consistent with Western countries. Patients with AD had a significantly decreased risk of lung cancer. Further investigation of genetic evidence linking AD to cancer is warranted.
Authors: Laura Frain; David Swanson; Kelly Cho; David Gagnon; Kun Ping Lu; Rebecca A Betensky; Jane Driver Journal: Alzheimers Dement Date: 2017-07-12 Impact factor: 21.566
Authors: Anne G Ording; Erzsébet Horváth-Puhó; Katalin Veres; M Maria Glymour; Mikael Rørth; Henrik T Sørensen; Victor W Henderson Journal: Alzheimers Dement Date: 2020-05-20 Impact factor: 21.566
Authors: Kimberly D van der Willik; Rikje Ruiter; Frank J Wolters; M Kamran Ikram; Bruno H Stricker; Michael Hauptmann; Annette Compter; Sanne B Schagen; M Arfan Ikram Journal: Neuroepidemiology Date: 2018-05-14 Impact factor: 3.282
Authors: Igor Akushevich; Julia Kravchenko; Svetlana Ukraintseva; Konstantin Arbeev; Alexander Kulminski; Anatoliy I Yashin Journal: Exp Gerontol Date: 2013-09-21 Impact factor: 4.032